Genetically informed drug design has been estimated to double the success rate of clinical drug development [40], for example the development of SLC30A8 antagonists as a potential therapy for type 2 diabetes [41,42]. This evidence concerns the gene SLC30A8 and type 2 diabetes mellitus.